Find clinical documentation and medical coding guidance for Eliquis (Apixaban). Learn about ICD-10 codes, HCPCS codes, and CPT codes related to Apixaban prescriptions and administration. This resource provides information on Eliquis dosage, drug interactions, and adverse effects for accurate healthcare documentation and billing. Understand DOAC prescribing information and ensure proper coding for optimal reimbursement and patient care.
Also known as
Other drug allergy
Adverse reaction to Eliquis/Apixaban.
Poisoning by apixaban
Toxic effect from excessive Eliquis intake.
Drug-induced thrombocytopenia
Low platelet count caused by Eliquis/Apixaban.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is Eliquis (Apixaban) being used for a specific condition?
When to use each related code
| Description |
|---|
| Anticoagulant, reduces stroke risk in AFib. |
| Anticoagulant, often used for DVT/PE. |
| Anticoagulant, alternative to warfarin. |
Coding for Eliquis/Apixaban requires specific dosage documentation for accurate billing and compliance with payer rules.
Incorrectly coding the indication for Eliquis use (e.g., atrial fibrillation vs. DVT) can lead to denials and audits.
Potential future risk: ensuring accurate coding differentiation between Eliquis and any subsequent biosimilars to avoid claim errors.
Q: What are the most effective strategies for managing Eliquis (Apixaban) reversal in cases of acute major bleeding?
A: Managing Eliquis (Apixaban)-related major bleeding requires a multifaceted approach. First, immediately discontinue Eliquis. Activated prothrombin complex concentrate (aPCC, such as 4-factor PCC) is the recommended first-line reversal agent due to its rapid onset and demonstrated efficacy in restoring hemostasis. If aPCC isn't available, consider andexanet alfa (Andexxa), a specific antidote for factor Xa inhibitors. Supportive care, including mechanical compression, surgical intervention, and transfusion of packed red blood cells or fresh frozen plasma, should be implemented concurrently based on the patient's clinical status and bleeding severity. Explore how implementing a standardized protocol for Eliquis reversal can enhance your institution's preparedness for these critical events. For specific guidance and the latest recommendations, consult the package insert and updated clinical practice guidelines.
Q: How does Eliquis (Apixaban) compare to warfarin in terms of efficacy and safety for stroke prevention in patients with non-valvular atrial fibrillation (NVAF)?
A: Clinical trials, such as ARISTOTLE, have demonstrated that Eliquis (Apixaban) offers a comparable or superior efficacy profile to warfarin in preventing stroke or systemic embolism in patients with NVAF. Specifically, Eliquis has been shown to reduce stroke risk and major bleeding events, particularly intracranial hemorrhage, compared to warfarin. Furthermore, Eliquis eliminates the need for routine coagulation monitoring (INR) and has fewer drug-food interactions, simplifying patient management. However, consider implementing regular renal function assessments for patients on Eliquis, especially those with pre-existing renal impairment. Learn more about the comparative effectiveness of DOACs like Apixaban versus warfarin for NVAF management by reviewing the latest clinical trial data and expert consensus guidelines.
Patient presents for medication management of nonvalvular atrial fibrillation (NVAF). The patient is currently prescribed Eliquis (apixaban), a direct oral anticoagulant (DOAC) indicated for stroke prevention in NVAF. Assessment includes review of current medication list, recent INR if available, bleeding risk assessment using tools such as HAS-BLED or similar, and discussion of potential drug interactions. Patient education provided on medication adherence, signs and symptoms of bleeding (e.g., easy bruising, unusual bleeding), and the importance of regular follow-up appointments. Treatment plan continues Eliquis (apixaban) at the current dosage of [insert dosage] twice daily. Risks and benefits of anticoagulation therapy, including bleeding risk and thromboembolic risk reduction, were discussed with the patient. Patient demonstrates understanding of medication instructions and potential adverse effects. Diagnosis: Nonvalvular atrial fibrillation. ICD-10 code: I48.91. Plan for ongoing monitoring of coagulation status and medication efficacy.